Back to top
more

SCYNEXIS, Inc. (SCYX)

(Delayed Data from NSDQ)

$6.81 USD

6.81
734,997

+0.66 (10.73%)

Updated Nov 25, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 27% (186 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

Research for SCYX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

INDUSTRY: Medical - Drugs

Reports for Purchase

Showing records 161 - 180 ( 19451 total )

Company: Esperion Therapeutics, Inc.

Industry: Medical - Drugs

Record: 161

11/06/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ampio Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 162

11/06/2020

Company Report

Pages: 6

3Q20: Began Nebulized Ampion Trial, OAK4 Path Forward Awaits FDA Response

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: GlycoMimetics, Inc.

Industry: Medical - Drugs

Record: 163

11/06/2020

Company Report

Pages: 6

3Q20 Update - Multiple Shots on Goal With Momentum Set to Build at ASH

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: Spectrum Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 164

11/05/2020

Company Report

Pages: 8

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Available: 12/05/2020

Research Provided by a Third Party

Company: Harpoon Therapeutics, Inc.

Industry: Medical - Drugs

Record: 165

11/05/2020

Company Report

Pages: 7

3Q20 Update - Multiple Catalysts by Year-End and Keep an Eye on HPN601

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: Avenue Therapeutics, Inc.

Industry: Medical - Drugs

Record: 166

11/05/2020

Company Report

Pages: 8

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Available: 12/05/2020

Research Provided by a Third Party

Company: Lannett Co Inc

Industry: Medical - Drugs

Record: 167

11/05/2020

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Harpoon Therapeutics, Inc.

Industry: Medical - Drugs

Record: 168

11/05/2020

Company Report

Pages: 6

Q3 Financials; HPN601 Nominated as First Pipeline ProTriTAC

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Harpoon Therapeutics, Inc.

Industry: Medical - Drugs

Record: 169

11/05/2020

Daily Note

Pages: 9

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cassava Sciences, Inc.

Industry: Medical - Drugs

Record: 170

11/05/2020

Company Report

Pages: 5

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Available: 12/05/2020

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 171

11/05/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 172

11/05/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Corcept Therapeutics Incorporated

Industry: Medical - Drugs

Record: 173

11/05/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Sage Therapeutics, Inc.

Industry: Medical - Drugs

Record: 174

11/05/2020

Company Report

Pages: 10

We See 2021 As A Critical Year; All Efforts On Track

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Relay Therapeutics, Inc.

Industry: Medical - Drugs

Record: 175

11/05/2020

Company Report

Pages: 79

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 150.00

Available: 12/05/2020

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 176

11/04/2020

Daily Note

Pages: 5

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Available: 12/04/2020

Research Provided by a Third Party

Company: Corcept Therapeutics Incorporated

Industry: Medical - Drugs

Record: 177

11/04/2020

Company Report

Pages: 7

Details cannot be displayed until the posted date of availability

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Available: 12/04/2020

Research Provided by a Third Party

Company: Bioasis Technologies Inc.

Industry: Medical - Drugs

Record: 178

11/04/2020

Company Report

Pages: 5

Shifting gears to R-D

Provider: Edison Investment Research Limited

Analyst: CALLOWAY N

Price: .00

Research Provided by a Third Party

Company: Lannett Co Inc

Industry: Medical - Drugs

Record: 179

11/04/2020

Company Report

Pages: 5

FY1Q21 Recap - Stabilization Mode

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Esperion Therapeutics, Inc.

Industry: Medical - Drugs

Record: 180

11/04/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party